Amgen declares $1.15 per share dividend
The board of directors for Thousand Oaks biotechnology company Amgen declared a $1.15 per share dividend March 3 for the second quarter of 2017. The dividend will be paid on June 8 to all stockholders of record as of the close of business on May 17. The company has a market cap of $130.1 billion Read More →
Read More →Requests for proposals overlook value of face-to-face communication
I’ve been in business for more than 30 years and in that time I’ve hired quite a few people. But in all that time, not once, did I hire a person based strictly on their resume and certainly I’ve never hired anyone without having met them first. In every instance, I felt it was important, Read More →
Read More →Genentech sues Amgen over biosimilar drug info
Roch AG subsidiary Genentech filed a lawsuit against Amgen claiming the Thousand Oaks-based company obstructed its investigation of whether the biosimilar Amgen is developing for Genentech’s cancer treatment Avastin violates the company’s patents, according to reports Feb. 20. Sales for Avastin, a treatment for lung, colon, ovarian and other types of cancer, reached $6.8 billion Read More →
Read More →
Mixed-use developments tapping into built-in demand
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen applies for FDA approval of Blincyto
Thousand Oaks-based Amgen submitted an application for Blincyto to the U.S. Food and Drug Administration, the company announced on Feb. 14. Amgen aims to gain approval for Blincyto to treat Philadelphia chromosome-positive relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The drug was previously granted breakthrough therapy designation and accelerated approval in December 2014. “Acute Read More →
Read More →Thousand Oaks Boulevard mixed-use project gets green light
The Thousand Oaks Planning Commission voted 3-1 to move ahead with the specific plan’s first mixed-use project on Feb. 13. Thousand Oaks-based Daly Group aims to turn the former Lupe’s Mexican restaurant at 1710 Thousand Oaks Boulevard into a three-story project featuring 36 apartments and close to 5,000 square feet of commercial space. The apartments Read More →
Read More →Our view: Amgen’s smart moves keep it poised to grow
From its perch in Thousand Oaks, Amgen continues to be one of the savvier companies in the biopharma space when it comes to navigating drug policy and drug pricing. It continues to win the battle to keep copycat biosimilars from eroding its core franchises while gaining approval for new drugs – the latest is for Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
